Alaunos Therapeutics and Xeris Biopharma Compared

Which small-cap medical company is the better stock investment?

Mar. 18, 2026 at 9:18am

Got story updates? Submit your updates here. ›

Alaunos Therapeutics (NASDAQ:TCRT) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but a head-to-head comparison shows Xeris Biopharma may be the better investment. Xeris has higher revenue, earnings, and institutional ownership, as well as a stronger consensus rating from analysts.

Why it matters

Investors looking to gain exposure to the small-cap medical sector have two potential options in Alaunos and Xeris. Understanding the relative strengths and weaknesses of each company can help inform investment decisions and identify the more promising long-term opportunity.

The details

Xeris Biopharma has higher revenue and earnings than Alaunos Therapeutics, and is trading at a lower price-to-earnings ratio, indicating it is currently the more affordable of the two stocks. Analysts also have a stronger consensus rating and higher potential upside for Xeris compared to Alaunos. Additionally, Xeris has stronger institutional ownership, suggesting larger investors see more potential in the company.

  • The analysis is based on data reported as of March 18, 2026.

The players

Alaunos Therapeutics

A clinical-stage oncology-focused cell therapy company developing adoptive T-cell receptor engineered T-cell therapies to treat multiple solid tumor types.

Xeris Biopharma Holdings

A biopharmaceutical company engaged in developing and commercializing therapies, including treatments for severe hypoglycemia, periodic paralysis, and Cushing's syndrome.

Got photos? Submit your photos here. ›

The takeaway

Based on the comparative analysis, Xeris Biopharma appears to be the more promising small-cap medical investment compared to Alaunos Therapeutics, with stronger financials, more favorable analyst sentiment, and greater institutional backing.